The growing global demand for cell and gene therapies (CGTs) is resulting in a manufacturing paradigm shift, reflecting the need to overcome a range of evolving new challenges and adapt to maintain rigorous safety and efficacy standards.
This month’s cover story looks at how the acceleration in CGT approvals in recent years not only highlights the potential of these therapies, but also underscores the growing demand for specialised and expanded manufacturing capabilities.
Also in this issue, a feature examines what lessons researchers can take from the Covid-19 pandemic to address the growing mpox public health emergency. Ten years after Bristol Myers Squibb’s (BMS) Opdivo, Merck & Co’s Keytruda were approved, they continue to be major revenue drivers for the respective companies. An opinion piece assesses the market entry strategies, pricing dynamics over time, and respective health technology assessments of both drugs.
Read the latest issue of Pharma Technology Focus for all this and insights, and analysis from the pharmaceutical industry.
You can also subscribe here to receive email notifications when a new issue is available.
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
